234 related articles for article (PubMed ID: 6607471)
1. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
[TBL] [Abstract][Full Text] [Related]
2. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Mitchell BS; Koller CA; Kelley WN
Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
[No Abstract] [Full Text] [Related]
4. Enzyme activities of leukemic cells and biochemical changes induced by deoxycoformycin in vitro--lack of correlation with clinical response.
Ho AD; Ganeshaguru K; Knauf W; Dietz G; Trede I; Hoffbrand AV; Hunstein W
Leuk Res; 1989; 13(4):269-78. PubMed ID: 2785618
[TBL] [Abstract][Full Text] [Related]
5. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
[TBL] [Abstract][Full Text] [Related]
6. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
Kefford RF; Fox RM
Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
[No Abstract] [Full Text] [Related]
7. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
[No Abstract] [Full Text] [Related]
8. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.
Lee N; Russell N; Ganeshaguru K; Jackson BF; Piga A; Prentice HG; Foa R; Hoffbrand AV
Br J Haematol; 1984 Jan; 56(1):107-19. PubMed ID: 6231047
[TBL] [Abstract][Full Text] [Related]
9. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic conversion of acute leukaemia from T-lymphoblastic to myeloblastic induced by therapy with 2'-deoxycoformycin.
Murphy SB; Stass S; Kalwinsky D; Rivera G
Br J Haematol; 1983 Oct; 55(2):285-93. PubMed ID: 6604543
[TBL] [Abstract][Full Text] [Related]
11. Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes.
Kefford RF; Fox RM
Br J Haematol; 1982 Apr; 50(4):627-36. PubMed ID: 6978147
[TBL] [Abstract][Full Text] [Related]
12. Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
Macdonald JS; Marsoni S; Bruno S; Poster D
Recent Results Cancer Res; 1982; 80():323-30. PubMed ID: 6977170
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
Prentice HG; Russell NH; Lee N; Ganeshaguru K; Blacklock H; Piga A; Smyth JF; Hoffbrand AV
Lancet; 1981 Dec; 2(8258):1250-4. PubMed ID: 6118669
[TBL] [Abstract][Full Text] [Related]
14. 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
O'Dwyer PJ; Wagner B; Leyland-Jones B; Wittes RE; Cheson BD; Hoth DF
Ann Intern Med; 1988 May; 108(5):733-43. PubMed ID: 3282467
[TBL] [Abstract][Full Text] [Related]
15. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of deoxycoformycin.
Major PP; Agarwal RP; Kufe DW
Blood; 1981 Jul; 58(1):91-6. PubMed ID: 6263381
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.
Bagnara AS; Hershfield MS
Proc Natl Acad Sci U S A; 1982 Apr; 79(8):2673-7. PubMed ID: 6283540
[TBL] [Abstract][Full Text] [Related]
18. Deoxyadenosine triphosphate accumulation in erythrocytes of deoxycoformycin-treated mice.
Smith CM; Henderson JF
Biochem Pharmacol; 1982 Apr; 31(8):1545-51. PubMed ID: 6980005
[TBL] [Abstract][Full Text] [Related]
19. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
20. Potential use of purine nucleosides and enzyme inhibitors for selective depletion of Thy-lymphoblasts from human bone marrow.
Russell NH; Hoffbrand AV; Bellingham AJ
Leuk Res; 1986; 10(3):325-9. PubMed ID: 3081767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]